Pure Global AI
NCT05929183Recruiting

Neuronavigation rTMS to Improve Depressive Episodes of Bipolar Disorder in Adolescent

Efficacy and Safety Study of Neuronavigation Occipital rTMS to Improve Depressive Episodes of Bipolar Disorder in Adolescent
First Affiliated Hospital of Zhejiang UniversityClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Bipolar Disorder
Drug/Device/Intervention
Repetitive Transcranial magnetic stimulation
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
First Affiliated Hospital of Zhejiang University
Location
Hangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2022
End date
Jul 30, 2023
Enrollment
50 participants
Primary outcome

Montgomery-Asberg Depression Rating Scale（MADRS）

Summary

The purpose of this study is to explore a new stimulation target and protocol for the
 treatment of depressive episode in adolescents with bipolar disorder through the repetitive
 transcranial magnetic stimulation(rTMS) under neuronavigation, and verify whether there is
 abnormal functional connectivity between the emotion-related brain area orbital frontal lobe
 (OFC) and the primary visual cortex(V1) during the depressive episode, which will contribute
 to further understand the relevant neural pathway and mechanism.

ICD-10 classifications
Bipolar affective disorderBipolar affective disorder, unspecifiedOther bipolar affective disordersBipolar affective disorder, currently in remissionBipolar affective disorder, current episode mixed
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05929183
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05929183 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital of Zhejiang University and is currently Recruiting. The study focuses on Bipolar Disorder. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.